Trial Profile
A Phase I Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of BCG and AERAS-404 Administered as a Prime-Boost Regimen to HIV-Negative, TB-Negative, BCG-Naive Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs H4IC (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Adverse reactions
- 21 Apr 2015 New trial record